Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
The University of Texas MD Anderson Cancer Center · The University of Texas at Austin · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
368
total citations
- FWCI
- 101.58
- Percentile
- 100%
- References
- 72
Citations per year
Authors
49- TATimothy A. YapCorresponding
The University of Texas MD Anderson Cancer Center
- NDNaval Daver
The University of Texas MD Anderson Cancer Center
- MMMikhila Mahendra
The University of Texas MD Anderson Cancer Center
- JZJixiang Zhang
The University of Texas MD Anderson Cancer Center
- CKCarlos Kamiya-Matsuoka
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Medicine
- Neurotoxicity
- Myeloid leukemia
- Pharmacology
- Tolerability
- Histone deacetylase inhibitor
- Leukemia
- Toxicity
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.